The ACME Laboratories Ltd. (DSE:ACMELAB)

Market Cap	15.24B
Revenue (ttm)	37.48B
Net Income (ttm)	2.51B
Shares Out	211.60M
EPS (ttm)	11.87
PE Ratio	6.06
Forward PE	n/a
Dividend	3.50 (4.86%)
Ex-Dividend Date	Nov 19, 2025

Volume	86,669
Average Volume	123,173
Open	71.30
Previous Close	70.90
Day's Range	70.70 - 72.30
52-Week Range	67.90 - 85.90
Beta	0.03
RSI	53.01
Earnings Date	Jan 27, 2026

About The ACME Laboratories

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacturing, marketing, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and ...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 9,025
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ACMELAB

Financial Performance

In 2025, The ACME Laboratories's revenue was 35.94 billion, an increase of 12.54% compared to the previous year's 31.93 billion. Earnings were 2.43 billion, a decrease of -1.12%.